NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO)


Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.


Ages Eligible for Study:   12 months to 21 Years

Genders Eligible for Study:   Both

Open and Recruiting

This study is currently recruiting participants.



Link: https://clinicaltrials.gov/ct2/show/NCT02679144